T-CURX

Würzburg, Germany

T-CURX develops personalized T cell therapies for cancer, leveraging a proprietary platform for improved patient outcomes.

$20.0M raised

Dec 2025

Series A

Top Investors

Bayern KapitalBioMedPartnersi&i Biotech FundHighLight Capital

19,000+ verified contacts

Emails, phones & LinkedIn profiles

How much funding has T-CURX raised?

T-CURX has raised $20.0M in total funding. The most recent round was Series A. The last funding was announced in December 2025.

Who are T-CURX's investors?

T-CURX's investors include Bayern Kapital, BioMedPartners, i&i Biotech Fund, HighLight Capital.

Where is T-CURX headquartered?

T-CURX is headquartered in Würzburg, Germany.

What does T-CURX do?

T-CURX develops personalized T cell therapies for cancer, leveraging a proprietary platform for improved patient outcomes.

What stage is T-CURX at?

T-CURX is at the Series A stage.

Cite this page

Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated December 17, 2025.

MLA

"T-CURX — Funding & Investors." VCBacked, December 17, 2025, https://www.vcbacked.co/company/t-curx. Accessed June 9, 2026.

APA

VCBacked. (2025). T-CURX — Funding & Investors. Retrieved June 9, 2026, from https://www.vcbacked.co/company/t-curx

Wikipedia (cite web)

{{cite web |title=T-CURX — Funding & Investors |url=https://www.vcbacked.co/company/t-curx |website=VCBacked |access-date=June 9, 2026}}

Profile data sourced and verified per the VCBacked methodology. Last funding round dated December 17, 2025.